Our results suggest that tepotinib inhibits Wnt/β-catenin signaling and the c-MET and ERK pathways by inhibiting c-MET and ERK phosphorylation and c-MYC and β-catenin expression in c-MET-positive GC cells. Here, MYC is linked to gastric cancer.